May 2005
Thorax;May2005, Vol. 60 Issue 5, p417
Academic Journal
The article presents information on a study which found that the development of a new mutant of epidermal growth factor receptor (EGFR) leads to drug resistance in non-small cell lung cancer. EGFR is frequently overexpressed and in an activated phosphorylated form in non-small-cell lung cancers (NSCLC). The majority of responsive tumors contain somatic mutations in the tyrosine kinase domain of the EGFR gene (small deletions or point mutations), which mediate the oncogenic effects but also confer the sensitivity to anilinoquinazoline inhibitors. The study reports the case of a patient with EGFR mutant (delL747-S752), gefitinib responsive, advanced NSCLC who relapsed after 2 years of complete remission with gefitinib treatment.


Related Articles

  • Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Ruiz, M. I. Galleges; Floor, K.; Steinberg, S. M.; Grünberg, K.; Thunnissen, F. B. J. M.; Belien, J. A. M.; Meijer, G. A.; Peters, G. J.; Smit, E. F.; Rodriguez, J. A.; Giaccone, G. // British Journal of Cancer;1/13/2009, Vol. 100 Issue 1, p145 

    The purpose of this study is to evaluate the prognostic value of the combined assessment of multiple molecular markers related to the epidermal growth factor receptor (EGFR) pathway in resected non-small cell lung cancer (NSCLC) patients. Tumour specimens of 178 NSCLC patients were collected and...

  • EGFR mutations in serum DNA predicted poor outcome after erlotinib. Lawrence, Leah // Hem/Onc Today;11/25/2008, Vol. 9 Issue 21, p29 

    The article discusses a study of the impact of erlotinib on patients with metastatic non-small cell lung cancer who had a mutated form of epidermal growth factor receptor (EGFR) gene, which was presented at the ASTRO-NCI-EORTC Annual Meeting in Florida. It evaluates tumor and serum EGFR...

  • O1–146RECHALLENGE WITH EGFR-TKI AFTER A DRUG HOLIDAY, RETROSPECTIVE STUDY IN SINGLE INSTITUTION. Kodani, M.; Igishi, T.; Sakamoto, T.; Touge, H.; Izumi, H.; Ito, S.; Kurai, J.; Yamaguchi, K.; Nakamoto, M.; Shimizu, E. // Annals of Oncology;Nov2013 Supplement 9, Vol. 24, pix44 

    No abstract available.

  • Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations. Liang, Wenhua; Wu, Xuan; Fang, Wenfeng; Zhao, Yuanyuan; Yang, Yunpeng; Hu, Zhihuang; Xue, Cong; Zhang, Jing; Zhang, Jianwei; Ma, Yuxiang; Zhou, Ting; Yan, Yue; Hou, Xue; Qin, Tao; Dinglin, Xiaoxiao; Tian, Ying; Huang, Peiyu; Huang, Yan; Zhao, Hongyun; Zhang, Li // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Background: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR mutations. However, no head to head trials between these TKIs...

  • The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. Sun, Jong-Mu; Won, Young-Woong; Kim, Seung; Kim, Jung; Choi, Yoon-La; Lee, Jeeyun; Park, Yeon; Ahn, Jin; Park, Keunchil; Ahn, Myung-Ju // Journal of Cancer Research & Clinical Oncology;Apr2011, Vol. 137 Issue 4, p687 

    Background: Epidermal growth factor receptor (EGFR) mutations are associated with sensitivity to gefitinib or erlotinib in non-small cell lung cancer (NSCLC). We investigated the relationships between the two most common types of somatic EGFR mutations, exon 19 deletions and L858R mutations, and...

  • Mutation predicted response to erlotinib in advanced NSCLC.  // Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p19 

    The article discusses a study which reported the benefit of erlotinib for treating patients with non-small cell lung cancer if they had epidermal growth factor receptor mutations. Data from the study were presented by Rafael Rosell, chief of the medical oncology service at the Catalan Institute...

  • Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer. Bing Wei; Ke Yang; Jiuzhou Zhao; Yuxi Chang; Zihui Ma; Bing Dong; Yongjun Guo; Jie Ma // Journal of Experimental & Clinical Cancer Research (17569966);2014, Vol. 33 Issue 1, p1 

    Background EGFR mutation detection has been widely applied in the prediction of TKIs therapy in Non-Small Cell Lung Cancer (NSCLC). Metastatic tumors rather than primary tumors were usually assayed for those patients in advanced stages. Although the difference of EGFR mutation status in primary...

  • Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Schmid, K; Bago-Horvath, Z; Berger, W; Haitel, A; Cejka, D; Werzowa, J; Filipits, M; Herberger, B; Hayden, H; Sieghart, W // British Journal of Cancer;8/24/2010, Vol. 103 Issue 5, p622 

    Background:In this report we investigated the combination of epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) pathway inhibition as a possible new therapeutic strategy for small cell lung cancer (SCLC).Methods:EGFR, p-AKT, p-ERK, p-mTOR and p-p70s6K protein...

  • Pulmonary.  // Modern Pathology;Jan2006 Supplement 1, Vol. 19, p301A 

    The article presents abstracts of medical research. They include "NFkB Expression in Neuroendocrine Neoplasms of the Lung," "Sarcomatoid Malignant Mesothelioma: Immunohistochemical Characteristics of 24 Cases," and "Epidermal Growth Factor Receptor in Non Small Cell Lung Cancer: Gene Copy Number...


Read the Article


Sign out of this library

Other Topics